Key Takeaway: Precision BioSciences has announced the granting of a U.S. patent for its PBGENE-HBV program, which targets chronic Hepatitis B and is protected until 2042. The Phase 1 ELIMINATE-B trial is currently progressing, with dosing for Cohort 3 set to begin in the third quarter of 2025. This development enhances the company's intellectual property and clinical advancement.
Price reaction · baseline $5.07 (2025-09-05 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-2%
Market Sentiment Analysis
POSITIVE FACTORS
U.S. patent protection strengthens intellectual property portfolio.
PBGENE-HBV program shows progress with ongoing clinical trials.
Cohort 3 dosing initiated, indicating advancement in the trial.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Strengthens the Company’s intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection into 2042- – Phase 1 ELIMINATE-B trial progressing through clinical investigation with dosing of Cohort 3 initiated in Third Quarter of 2025- DURHAM, N.C.
Frequently Asked Questions
What is PBGENE-HBV?
PBGENE-HBV is Precision BioSciences' lead program targeting chronic Hepatitis B.
How long is the patent protection for PBGENE-HBV?
The U.S. patent for PBGENE-HBV is protected until 2042.
What is the status of the ELIMINATE-B trial?
The Phase 1 ELIMINATE-B trial is progressing, with Cohort 3 dosing starting in Q3 2025.
Where is Precision BioSciences located?
Precision BioSciences is based in Durham, North Carolina.